Skip to main content

Table 2 Inclusion and exclusion criteria for NEXT and VENICE

From: Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia

Inclusion criteria Exclusion criteria
• Adult patients (NEXT) • Chronic myeloid leukaemia
• Adult and paediatric patients (VENICE) • Myelodysplastic syndrome
• Solid tumours or haematological malignancies • Hypersensitivity to the active substance
• Treated or planned treatment with cytotoxic chemotherapy irrespective of cycle • Hypersensitivity to one of the excipients of Nivestim™
• Indicated for G-CSF therapy according to the product label for Nivestim™ • Undergoing treatment with G-CSF for ongoing FN (curative) (VENICE only)*
  1. *NEXT includes two patient profiles: curatively and prophylactically treated patients; VENICE includes only patients treated prophylactically. Patients are not excluded if they have congenital neutropenia disorders or have received stem cell transplants.